Methyleugenol is a phenylpropanoid found in rose, basil, pimento, and other aromatic materials, where it contributes a sweet spicy floral-clove nuance. Its evidence base is strongest for identity, natural occurrence, insect-attractant ecology, and toxicology. Public safety authorities and animal toxicology literature consistently treat methyleugenol as a compound requiring caution because rodent studies support carcinogenic concern after oral exposure, so AromaForge should present it as an analytically important aroma constituent with notable regulatory and safety relevance rather than as a wellness-active ingredient.
Chemical identity and composition
NIST lists methyleugenol as C11H14O2, CAS 93-15-2, with common synonyms including eugenyl methyl ether and O-methyleugenol. In the archive it appears as a secondary but important rose and spice-floral marker. Its toxicology literature often groups it with other allylalkoxybenzenes such as estragole and safrole because metabolic activation of the allylic side chain is central to the hazard discussion.
Aroma and practical use
- Use the recorded spicy, clove-like, warm, carnation-like, sweet descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
rodent carcinogenicity
The NTP Report on Carcinogens summarizes that oral methyleugenol exposure caused benign or malignant liver tumors in rats and mice of both sexes and additional stomach, kidney, mammary-gland, and skin tumors in some groups, supporting its listing as reasonably anticipated to be a human carcinogen.
Measured: tumor incidence across multiple tissues
This experimental finding does not establish benefit, dose or safety in people using this blend.
human exposure biomonitoring
A human consumption study examined serum elimination after methyleugenol intake, showing that this naturally occurring flavor constituent is measurable in humans and can be tracked through biomonitoring-style exposure assessment.
Measured: serum methyleugenol kinetics after dietary exposure
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
dna adduct formation
A human-liver study reported that methyleugenol DNA adducts were associated with SULT1A1 copy number and expression, strengthening the evidence that metabolic activation capacity shapes individual susceptibility.
Measured: methyleugenol-associated DNA adduct detection
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe National Toxicology Program lists methyleugenol as reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The European food-science opinion located for this pass describes methyleugenol as a naturally occurring genotoxic carcinogen and recommends ensuring its absence from intentionally added food flavoring contexts.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
For AromaForge, methyleugenol should be summarized as a constituent with notable regulatory and toxicological relevance, not as a broadly beneficial wellness constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EstragoleOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Estragole report →EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Eugenol report →EstragoleOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · effect
No source citation attached.
Read Estragole report →How the effects were investigated
metabolic activation to dna reactive intermediates
The NTP Report on Carcinogens states that methyleugenol may be bioactivated by 1-prime hydroxylation followed by sulfation, epoxidation of the allylic double bond, or O-demethylation pathways, with the hydroxylation route particularly implicated in DNA-reactive intermediate formation and liver tumorigenesis.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
dna adduct formation in human relevant models
Human-liver and hepatocyte studies reported methyleugenol-associated DNA adduct formation after metabolic activation, supporting the mechanistic link between biotransformation and genotoxic concern.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical benefit studies specific to isolated methyleugenol were verified in this pass.
- Most constituent-specific literature is toxicology, biomonitoring, or mechanism oriented rather than efficacy oriented.
- Because toxicology dominates the evidence base, archive SEO language should stay restrained and avoid implying consumer-health benefit.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.